Things are definitely not perfect for Accuray (NASDAQ:ARAY) yet, but the story continues to improve on a quarter by quarter basis. Assuming that the company can successfully convert orders to installations and revenue, the company is gaining share from Varian (NYSE:VAR) and Elekta (OTCPK:EKTAY) and rebuilding credibility that this can once again become a med-tech growth story.
Many things can still go wrong, as the company's order level is still below where it needs to be to be a viable business and the long-term margin structure is a significant unknown. This is also still a volatile stock, as investors have seen these shares trade down recently on worries about reimbursement in the radiation oncology...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|